Find out how these stocks survived a horrible day for the market.
News & Analysis: MediciNova
The biopharma stopped a clinical trial early after a drug candidate showed impressive efficacy.
Lower-than-expected pricing for a secondary offering just took the shine off recently announced trial data.
These five stocks moved higher this past week.